The larger attachment glycoprotein of respiratory syncytial virus produced in primary human bronchial epithelial cultures reduces infectivity for cell lines
Open Access
- 8 April 2021
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS Pathogens
- Vol. 17 (4) , e1009469
Abstract
Respiratory syncytial virus (RSV) infects the upper and lower respiratory tracts and can cause lower respiratory tract infections in children and elders. RSV has traditionally been isolated, grown, studied and quantified in immortalized cell lines, most frequently HEp-2 cells. However, in vivo RSV infection is modeled more accurately in primary well differentiated human bronchial epithelial (HBE) cultures where RSV targets the ciliated cells and where the putative RSV receptor differs from the receptor on HEp-2 cells. The RSV attachment (G) glycoprotein in virions produced by HEp-2 cells is a highly glycosylated 95 kDa protein with a 32 kDa peptide core. However, virions produced in HBE cultures, RSV (HBE), contain an even larger, 170 kDa, G protein (LgG). Here we show that LgG is found in virions from both subgroups A and B lab-adapted and clinical isolates. Unexpectedly, RSV (HBE) virions were approximately 100-fold more infectious for HBE cultures than for HEp-2 cells. Surprisingly, the cause of this differential infectivity, was reduced infectivity of RSV (HBE) on HEp-2 cells rather than enhanced infectivity on HBE cultures. The lower infectivity of RSV(HBE) for HEp-2 cells is caused by the reduced ability of LgG to interact with heparan sulfate proteoglycans (HSPG), the RSV receptor on HEp-2 cells. The discovery of different infectivity corresponding with the larger form of the RSV attachment protein when produced by HBE cultures highlights the importance of studying a virus produced by its native host cell and the potential impact on quantifying virus infectivity on cell lines where the virus entry mechanisms differ from their natural target cell.Keywords
Funding Information
- National Institute of Health (F31 Al143234)
- National Institute of Health (R01 Al093848)
- National Institute of Health (P01 Al112524)
- National Institute of Health (P01 Al112524)
- National Institute of Health (P01 Al112524)
- Cystic Fibrosis Foundation Therapeutics, Inc. (MCCOY17R2)
This publication has 38 references indexed in Scilit:
- Enzyme-catalyzed protein crosslinkingApplied Microbiology and Biotechnology, 2012
- Transglutaminase 2: A molecular Swiss army knifeBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2012
- A highly attenuated recombinant human respiratory syncytial virus lacking the G protein induces long-lasting protection in cotton ratsVirology Journal, 2010
- Vaccination To Induce Antibodies Blocking the CX3C-CX3CR1 Interaction of Respiratory Syncytial Virus G Protein Reduces Pulmonary Inflammation and Virus Replication in MiceJournal of Virology, 2010
- Respiratory Syncytial Virus Grown in Vero Cells Contains a Truncated Attachment Protein That Alters Its Infectivity and Dependence on GlycosaminoglycansJournal of Virology, 2009
- Infection of Ciliated Cells by Human Parainfluenza Virus Type 3 in an In Vitro Model of Human Airway EpitheliumJournal of Virology, 2005
- Recombinant Human Metapneumovirus Lacking the Small Hydrophobic SH and/or Attachment G Glycoprotein: Deletion of G Yields a Promising Vaccine CandidateJournal of Virology, 2004
- Major changes in the G protein of human respiratory syncytial virus isolates introduced by a duplication of 60 nucleotidesJournal of General Virology, 2003
- Multiple heparin binding domains of respiratory syncytial virus G mediate binding to mammalian cellsArchives of Virology, 2003
- The Central Conserved Cystine Noose of the Attachment G Protein of Human Respiratory Syncytial Virus Is Not Required for Efficient Viral Infection In Vitro or In VivoJournal of Virology, 2002